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Abstract:  
Introduction: Combination Antiretroviral Therapy (cART) has not allowed the cure of HIV. The 
main obstacle to HIV eradication is the existence of quiescent reservoirs. Several other 
limitations of cART have been described, such as strict life-long treatment and high costs, 
restricting it to Western countries, as well as the development of multidrug resistance. Given 
these limitations and the impetus to find a cure, the development of new treatments is 
necessary.  
Areas covered: In this review, we discuss the current status of several efficient molecules 
able to suppress HIV gene transcription, including NF-kB and Tat inhibitors. We also assess 
the potential of new proteins belonging to the intriguing DING family, which have been 
reported to have potential anti-HIV-1 activity by inhibiting HIV gene transcription.  
Expert opinion: Targeting HIV-1 gene transcription is an alternative approach, which could 
overcome cART-related issues, such as the emergence of multidrug resistance. Improving 
cART will rely on the identification and characterization of new actors inhibiting HIV-1 
transcription. Combining such efforts with the use of new technologies, the development of 
new models for preclinical studies, and improvement in drug delivery will considerably reduce 
drug toxicity and thus increase patient adherence.  
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Article highlights 
• Adding to cART drugs which block the production including the virus transcription 
could be a significant improvement since this could prevent cART-related side 
effects like multidrug resistance. 
• Intensifying cART with transcriptional inhibitors will help to reduce the size of 
latent reservoirs, to reduce the prevalence of HAND and to prevent brain injuries 
in strategies aiming to reactivate and eliminate the brain reservoirs. 
• NF-kB and Tat are the two main targets for the improvement of cART. These 
targets control HIV progression by activating transcription.  
• Most of the potential transcriptional inhibitors still await preclinical and clinical 
trials. 
• Improvement of cART relies on identification of new targets, development of 
adequate animal models and introduction of new technologies. 
• In the next 10 years, new drugs and methods to increase bioavailability and bio-
distribution may allow at least a functional cure including strategies aiming at the 
reduction of the pool of latent reservoirs. 
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1. Introduction 
 
Introduction of combination Antiretroviral Therapy (cART) in 1996 has dramatically 
improved the management of HIV-1 infection and decreased both morbidity and mortality. 
However, despite initial hopes to cure HIV, the treatment is unable to eradicate the virus 
[1,2]. Very sensitive methods always detect a residual viremia in patients on cART [3,4]. 
Moreover, HIV RNAs return to a measurable plasma level when cART is interrupted [5,6]. 
The origin of the persistent viremia is still debated [7–9]. In the latent phase, HIV proviruses 
persist in long lived cells such as the central memory CD4+ T-cells, hematopoietic stem cells, 
dendritic cells and cells from the monocyte-macrophages lineage including the microglial 
cells, i.e. the resident macrophages of the central nervous system (reviewed in [10]). For 
example, latently infected cells reactivated by pro-inflammatory cytokines that produce HIV 
particles at low levels (well known as “Blips”) could explain persistent viremia. An alternative 
theory, the cryptic ongoing replication states that HIV persists in cells continuously producing 
low levels of HIV despite cART. The inefficient treatment of ongoing replication supporting 
cells could either be due to poor drug penetration into sanctuaries as the brain [11] or to cell-
to-cell transfer of the virus [12]. The resistance against drugs in cART arising during ongoing 
replication has profound therapeutic implications. We therefore expect that intensification of 
cART reduces persistent viremia. 
 The various limitations of the current antiretroviral therapy makes cART unable to 
achieve a cure. The combination of drugs used in cART acts at different stages of the viral 
life cycle; cART needs lifelong drug adherence since ultimately HIV rebounds after cART 
interruption; there are severe side effects of the treatment including neurocognitive disorders, 
hyperlipidemia, nephrotoxicity, hepatotoxicity, lipodystrophy. Finally, the cost of the treatment 
is still excessive and therefore access is limited in poor countries. The latter is a major 
problem; more than 7000 new HIV infections occur every day and the number of newly 
diagnosed infections remains far greater than the number of people who have access to 
cART. Another major concern is the emergence of drug resistance that arises from the 
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extreme mutability of the virus [13–16]. Overall, the life expectancy of infected patients on 
cART is still reduced compared to non-infected individuals [17]. Indeed, chronic inflammation 
from residual viremia leads to several non AIDS related complications i.e. cardiopathy, 
nephropathy, faster progression towards hepatitis C complications and cancer [18]. 
Moreover, extracellular Tat resulting from residual viremia is responsible for Tat-associated 
cancer and HIV-associated neurocognitive disorder (HAND) [19]. 
In view of these limitations, new classes of drugs which preferably act on new targets 
of HIV replication should replace or partially substitute the existing ones. Original strategies 
focusing on the purge of quiescent reservoirs are also needed to completely eradicate the 
virus (reviewed in [20]). It was suggested that intensifying cART effects residual viremia and 
prevents the development of non-AIDS events. Except in one case [21], the benefit of the 
intensification of cART on residual viremia was not conclusive in the studies (reviewed in [9]).  
 
Recently cART has been somewhat improved. New antiretroviral drugs and drug 
combinations, with good tolerability and efficiency against drug resistant viruses are currently 
tested in clinical trials [22]. Drugs used in combinations in cART target four stages of the 
cycle: viral entry, reverse transcription of the viral genome, integration into the genome of the 
host cell and maturation of viral proteins. However, to date, no drug developed so far targets 
the first step of the production phase, HIV gene transcription. Besides transcription other 
processes of viral gene expression i.e. splicing, polyadenylation, RNA nuclear export, 
translation, packing, dimerization etc, also deserve attention (Figure 1). Targeting these 
processes can all inhibit virus production or produce non-infectious particles. A recent study 
suggests that the drug ABX464 targeting the viral protein Rev involved in RNA export has a 
sustained antiviral effect in a humanized mouse model [23]. This striking observation needs 
however further investigation; one cannot exclude that it arises from an artefact of the animal 
model (comments in [24]).  
We focus in this review on HIV transcriptional inhibitors. We believe that targeting HIV-
1 gene transcription is an alternative approach that could overcome cART-related issues 
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such as the emergence of multidrug resistance or the progression to HAND and therefore 
should be seriously considered. After a brief description of the mechanisms involved in HIV-1 
transcription, we discuss recent advances in the discovery of HIV inhibitors of the two main 
targets for HIV-1 transcription control i.e. NF-KB and Tat. We then discuss a new family of 
promising targets, the DING protein family. These drugs repress HIV-1 transcription and 
have anti-inflammatory properties. Finally, we discuss routes to improve cART, with a special 
focus on drugs targeting HIV-1 transcription. The new therapeutic methods might reinforce 
current cART and at the same time prevent chronic inflammation and some pathologies 
related to extra cellular Tat such as HAND and Tat-related cancer. 
 
2. Regulation of HIV-1 gene transcription 
Once the HIV provirus is integrated into the host cell genome, virus transcription can 
occur (Figure 1). HIV-1 gene transcription is a critical step in infected cells where the virus 
exploits the cellular environment in order to maximize gene expression. Transcription is 
regulated by the interplay of distinct viral and cellular transcription factors that bind the Long 
Terminal Repeat (LTR) region of HIV-1 (reviewed in [25,26]). This LTR region comprises four 
functional regions related to HIV-1 transcription regulation: (i) the Transactivator Response 
(TAR) binds Tat; (ii) the core promoter contains a TATA-box, an initiator and three Sp1 
binding sites; (iii) the core enhancer contains NF-AT and NF-KB motifs. According to 
previous reports, the three SP1 binding sites and the two NF-KB motifs play important roles 
in the regulation of HIV-1 transcription. (iv) The modulatory region harbors numerous target 
sequences for cellular transcription factors such as c-Myc, COUP-TF, NF-IL6, Nuclear 
Hormone responses [26]. Deletion of this region enhances HIV-1 transcription and replication 
suggesting the presence of a negative regulatory element (NRE) [26,27]. 
Infected cells have two fates depending on the local state of chromatin structure and on 
the cellular environment [10]. On the one hand, in the relaxed state of chromatin i.e. 
euchromatin there is an active transcription and infected cells are productive. On the other 
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hand, in the compact and very structured state of chromatin i.e. heterochromatin there is no 
transcription and infected cells become latent and/or quiescent. 
 
i. Transcriptional status in productively infected cells 
The early phase of transcription 
Once the HIV-1 promoter is open to the transcriptional machinery, a cellular-dependent 
early phase complex initiates gene transcription (figure 1 and 2). Multi-spliced RNAs 
encoding viral regulatory proteins including Tat, Rev and Nef are then transcribed. Reference 
[26] reviews the mechanism by which transcription of the viral genome adjusts to specific cell 
types. NF-KB and NF-AT translocate into the nucleus upon activation in T-lymphocytes [28]. 
Binding of NF-KB and NF-AT to the promoter is a prerequisite for activation of transcription. 
In contrast, Sp1 and other general transcription factors bind to the core region. Additional 
factors such as NF-IL6, CREB, USF and Ets are however required for full activation [26]. On 
the other hand, in microglial cells the core region and the NF-KB sites are sufficient for 
transcription. The inhibition of NF-KB activation and its signaling pathway offers therefore a 
promising strategy for anti-HIV therapy [29]. 
 
The late phase of transcription 
The late phase of transcription is under the control of the viral protein Tat. Tat amplifies 
gene expression by affecting the initiation and elongation phases of transcription (figure 1 
and 2). The scheme of Tat induced gene expression is as follows: Tat together with cyclin T1 
bind to the TAR RNA structure. This complex subsequently recruits the cyclin dependent 
kinase 9 (Cdk9) to form the positive transcription factor b (p-TEFb) [30,31]. The p-TEFb 
complex induces the phosphorylation of the carboxyl-terminal domain (CTD) of RNA 
polymerase II and the phosphorylation of the negative elongation factors NELF and NSIF 
therefore circumventing their inhibitory effect [32,33]. Interestingly, Tat exists in two P-TEFb-
associated complexes [34]. Tat-com1 includes MLL fusion partners and the PAF1 complex 
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and potentiates Tat-mediated transactivation, while Tat-com2 contains P-TEFb, the 7SK 
snRNA, LARP7, MEPCE and represses Tat functions. Indeed association of the small 
nuclear RNA 7K and the RNA-binding proteins HEXIM1, HEXIM2, LARP7 and MEPCE to the 
p-TEFb complex reversibly inhibits p-TEFb activity [35–38]. This large, inactive form of p-
TEFb (in contrast to its free, active form) is thought to be involved in HIV-1 transcription. HIV-
1 evades normal cellular control since Tat selectively recruits free p-TEFb complexes from 
the large pool of inactive p-TEFb complexes [39–42]. In turn the active p-TEFb promotes the 
transition of RNA pol II from abortive to productive elongation. Tat may also play an 
important role in the initiation of transcription and in the assembly of the general transcription 
factors [43]. In fact, ChIP analyses revealed that Tat increases the binding of several general 
transcription factors, including RNA pol II, TBP and TFIIB [44]. Tat also requires the 
presence of Sp1 and NF-KB sites and direct interaction with Sp1 protein for transactivation 
[45–47]. Moreover, Tat can modulate the expression of various cellular factors involved in the 
regulation of the HIV-1 gene transcription such as the cytokines TNF, TGF, IL2, IL6 and 
IL10 [48,49]. Recently, a genome-wide binding map of Tat has been performed. It showed 
that Tat was associated to several promoters involved in immune response and T-cell 
functions with important implications for the HIV-1 life cycle [50–52]. The precise mechanism 
of action of Tat on the regulation of cellular gene is not fully understood. A recent work using 
a global analysis of chromatin shed light on how Tat could modulate cellular gene 
expression. They showed that Tat is recruited on many promoter sites occupied by the 
transcription factor ETS1 [53]. Apart from its role in HIV-1 and cellular gene expression, 
many other functions of Tat have been described [54]. Notably, extra cellular Tat has been 
involved to the development of HIV-associated neurocognitive disorders [19]. The precise 
mechanism of HIV-1 Tat neurotoxicity remains unclear. It involves deregulation of calcium 
homeostasis, oxidative stress, altered mitochondrial biogenesis [19], alteration of autophagy 
function [55], deregulation of pathway that involved p53 and p73 [56]. Extracellular Tat 
constitutes a key molecule in HIV pathogenesis even if the exact mechanism of action 
inducing neuronal dysfunction is still debated. Furthermore, inhibition of extracellular Tat 
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activity might also help to reduce Tat-associated pathologies such as AIDS-associated 
cancer and HAND. 
All in all, the remarkable advances in recent years in the comprehension of Tat 
functions make it a potential therapeutic target for HIV-1. 
 
ii. Transcriptional status in abortively infected cells 
The switch from active to repressive transcription of HIV depends on chromatin-
modifying agents. These molecules modify the epigenetic marks of DNA and histone 
proteins. Indeed, heterochromatin is associated with CpG islands methylation and histone 
lysine trimethylation such as H3K9me3 and H3K27me3 [57–59]. In microglial cells a new 
level of eukaryotic gene regulation was suggested. It was shown that LSD1 and Bcl11b 
(CTIP2) were associated with the epigenetic marks H3K4me3 and H3K9me3 [60]. Numerous 
cellular factors have been characterized in the establishment and persistence of HIV latency 
in the main cellular reservoirs including CD4+ T-cells and microglial cells [61]. In this latter, 
our laboratory has demonstrated the importance of Bcl11b in inducing both establishment 
and persistence of HIV latency [reviewed in (62,63)]. Briefly, this protein serves as a platform 
anchoring a protein complex which include HDAC1, HDAC2 and the histone 
methyltransferase SUV39H1, which are involved in the establishment of HIV latency [59,64]. 
Preventing reactivation of HIV Bcl11b enables the persistence of HIV [65]. Bcl11b also 
interacts with the inactive p-TEFb complex containing HMGA1 and the CDK9 kinase activity 
of p-TEFb is inhibited by Bcl11b. Furthermore, HMGA1 and Bcl11b working in synergy 
repress gene transcription [66]. It is fundamental to understand the molecular mechanisms 
involved in these processes and deserves far more attention since it is a prerequisite for the 
development of alternative strategies i.e. (1) the reactivation of the reservoirs in “shock and 
kill” strategy and (2) the inhibition of HIV transcription. In strategy 1, the identification and 
characterization of new cellular targets involved in the reactivation of HIV transcription 
depends much on the understanding of the mechanisms. This strategy which might lead to 
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functional cure, known as “shock and kill”, aims to purge or at least to shrink the cellular 
reservoirs. This method implies the reactivation of HIV transcription (shock) followed by an 
intensive cART (kill) [67]. Other promising approach to purge the reservoirs is gene therapy 
that target the core receptor CCR5 discussed elsewhere [20]. Several recent reports 
suggested that new inhibitors used alone or in combination could be efficient for reactivating 
quiescent/latent HIV both in vitro, ex vivo and in vivo ([68] and reviewed in [69]).  
In the following sections, we focus on the second strategy which aims to control HIV-1 
progression by transcriptional inhibitors. 
 
3. Transcriptional inhibitors to control HIV-1 progression 
The control of HIV-1 progression by transcriptional inhibitors is of great interest since no 
drugs have been developed to date to target this step. To achieve this, one should design 
drugs targeting cellular cofactors involved in the activation of transcription. The strategy has 
to by-pass drug-resistance problems that arise with viral proteins. Numerous transcriptional 
inhibitors have been studied and demonstrated their efficacy in suppressing HIV transcription 
and/or inducing latency [70]. Strategies which effect transcriptional activators such as NF-AT 
or NF-IL6 also deserve attention. It has been shown that NF-IL6 is crucial for HIV-1 
transcription in the monocyte-macrophage cell lineage including microglial cells [71]. 
C/EBP, a truncated form of NF-IL6, acts as a transdominant negative repressor of HIV 
transcription (figure 2). Activation of C/EBP might be interesting and deserves further 
evaluation. Nevertheless, NF-B and Tat are the two main targets that control HIV 
progression by inhibiting transcription. Transcriptional gene silencing based on RNA 
interference (RNAi) is an alternative strategy [72,73]. Combinatorial gene therapy using 3 
siRNAs targeting tat and rev holds promise in achieving a functional cure. A nucleolar TAR 
decoy has been tested as part of this initial combinatorial gene therapy but didn’t provide yet 
additional benefit in inhibiting HIV replication [73]. This RNAi based approach provides a new 
way to combat HIV-1 infection and merits more attention.  
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3.1 NF-B inhibitors  
Among other candidates, the inducible transcription factor NF-KB deserves attention 
since it initiates the early phase of HIV transcription leading to the synthesis of the Tat 
transactivator. Inhibition of the NF-KB signaling pathway by various molecules has been 
reported in the literature [74]. However to date none of these molecules have been approved 
for clinical trials due to their ineffectiveness and/or potential toxicities. A major limitation of 
these drugs is that they target the NF-KB signaling pathway upstream to IKB degradation. 
Development of new inhibitors that target the late steps of the NF-KB signaling pathway, i.e. 
IKB degradation and DNA binding of NF-KB, is in progress. Among these molecules, 
quinoline derivatives are of interest since some of these inhibit HIV transcription [75–78]. 
Among 18 tested quinoline-based compounds , 3 were very active in vitro and ex vivo. 
Moreover, they indirectly affected HIV transcription by blocking the nuclear translocation of 
NF-KB and inhibiting Sp1 [79]. A new series of natural and substituted olean-18-ene 
triterpenoids were recently isolated from Celastraceae species and their structures 
elucidated. These displayed potent antiviral activities [80]. Interestingly, the molecules 
inhibited HIV-1 transcription by targeting both Sp1 and NF-KB, as reported for the quinolone 
derivatives as well. Another newly discovered NF-KB inhibitor, 
dehydroxymethylepoxyquinimycin (DHEMEQ) is also promising since it decreases HIV-LTR 
transcriptional activity mediated by external stimuli such as TNF or Tat [81]. DHMEQ 
inhibits NF-KB by specifically binding to it, and inhibiting its subsequent nuclear translocation 
[82,83]. Natural compounds are another source of drug discovery [84]. A screening program 
to isolate natural compounds with anti-HIV activities has identified the molecule denbinobin 
from a variety of Cannabis sativa [85]. This phenanthrene (1,4-phenanthrenequinone) 
molecule inhibits HIV transcription by preventing NF-KB binding to DNA and by affecting IkB 
phosphorylation and its subsequent degradation [86]. Lignins and small molecules having 
lignin-like structural functional groups also inhibit NF-KB and HIV-1 transcription [87]. A high-
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throughput RNA interference screening has recently identified a deubiquitinase named CYLD 
which has the property to repress HIV-1 transcription in a NF-AT/NF-KB dependent manner 
[88]. Finally, a specific myeloid cell factor, COMMD1/murr1 has been recently described as a 
new inhibitor of the HIV-1 transcription factor [89]. This factor inhibits NF-B activity by 
stabilizing I-B thus promoting HIV-1 latency. All these newly identified NF-KB inhibitors 
constitute potential anti-HIV-1 drugs and can pave the way to the development of new 
classes of drugs. Moreover, targeting NF-KB possibly reduces chronic inflammation (non-
AIDS associated pathologies) [90,91]. 
However, some limitations of the NF-KB inhibitors should be mentioned. One may 
expect side effects when targeting cellular factors involved in numerous cellular processes. 
Furthermore, according to reports, HIV-1 subtypes differ in the basic transcription factor 
binding sites and this may affect their responsiveness to drugs. Indeed, the conversion of the 
NF-KB binding site into a GABP binding site has been described in subtype E of HIV. This 
caused severe loss of NF-KB binding [92]. Response to these NF-KB inhibitors may not work 
in patients infected with this subtype of HIV-1.  
 
3.2 Tat inhibitors 
The viral protein Tat associated to the elongation factor pTEF-b plays a critical role in 
transcription and constitutes a major therapeutic target of the HIV replication [93,94]. The 
recent determination of the crystal structure of Tat-pTEFb has given new insights of the 
mechanism of Tat activation and may help in the design of new Tat inhibitors [95,96]. 
Targeting pTEFb could also lead to the inhibition of HIV transcription and the decrease of 
resistance to the virus. There are several ways to inhibit Tat functions: (i) targeting the 
elongation complex pTEFb mainly by inhibiting the catalytic subunit CDK9 of pTEFb (ii) 
targeting the Tat-pTEFb interaction, (iii) directly targeting Tat, (iv) or targeting the Tat-TAR 
association. 
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(i) Targeting pTEFb 
Several inhibitors of components from the pTEFb complex i.e. cyclin T1 and the 
catalytic subunit CDK9 that includes the nucleotide analogue DRB, flavopiridol and R-
roscovitine have been described [97]. However, due to the low therapeutic index, these 
molecules need further optimization before clinical trials. A recently designed derivative of 2-
phenylquinazolinone, a potent CDK9 inhibitor, has shown interesting properties [98]. The 
probable side effects are another major limitation to the development of pTEFb inhibitors 
since pTEFb is a master regulator of gene transcription.  
(ii) Targeting the Tat-pTEFb interaction 
Targeting specifically the Tat-pTEFb interaction appears more promising. Several 
inhibitors of the Tat-pTEFb interaction including celastrol [99] and cyclopentenone 
prostaglandin 15d PGJ2 have been described [100]. These two inhibitors interact with Tat and 
induce covalent bond formation with the cysteine thiols of Tat preventing pTEFb recruitment. 
However, their therapeutic indexes were too low, essentially due to high toxicity. Structure-
based analysis of CDK9 along with published Tat derivatives showed that short Tat peptides 
can prevent Tat-CDK9 interaction. New drug mimetics inhibiting CDK9 and inhibitors 
targeting the Cyclin T1-Tat interaction were found by in silico analysis [101,102]. Finally, 
recent advances such as Nuclear Magnetic Resonance (NMR) and Circular Dichroism (CD) 
have allowed the synthesis of a series of new Tat/TAR inhibitors [103]. A series of 
pentameric “poly amino acids” (PAAs) molecules have been shown to interact with Tat on the 
same TAR binding site. However, according to a comparative thermodynamic study of 
PAA/TAR, there are two different TAR binding modes for Tat (the competitor and the non-
competitor modes). Fragment-based screening is another new way to design drugs 
(reviewed in [104]). This approach aims to target the Tat-TAR interaction. Protein fragments 
bound to a target (the TAR RNA for example) are screened by various methods such as X-
ray crystallography, Nuclear Magnetic Resonance (NMR), Surface Plasmon Resonance 
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(SPR) and Differential Scanning Fluorimetry (DSF). These methods alone or in combination 
have already led to the discovery of novel inhibitory sites within HIV protease, reverse 
transcriptase and integrase. The fragment-based screening is now used to explore new 
inhibiting sites of the Tat/TAR interaction [105]. Although in its early stage, these studies 
illustrate the efficacy of modern spectroscopic technologies for the design new drugs. 
(iii) Targeting Tat 
A derivative of coumarin was found to inhibit HIV-1 Tat-mediated transcription. The 
inhibitory mechanism involves the repression of the Akt pathway which leads to the decrease 
of p300 stability, a protein known to modulate Tat activity by acetylation [106]. Another very 
promising Tat inhibitor has been recently isolated from the plant Triptoperygium wilfordii 
[107]. The molecule named triptolide is a diterpenoid epoxide that inhibits both HIV 
replication and transcription by increasing the proteasomal degradation of Tat. This molecule 
is currently in phase III of a clinical trial. Another natural product derivative, tanshinone from 
the root of Salvia miltiorrhiza deserves attention. It inhibits Tat-regulated transcription by 
inhibiting the AMPK/Namt/Sirt1 pathway [108]. Using a high-throughput screening assay, a 
new Tat inhibitor named 6 bromoindirubin 3’ oxime (6BIO) has been recently isolated [109]. 
This small molecule and its derivatives named 18BIOder inhibit a GSK-3 kinase. 
Interestingly this kinase is found in the GSK-3complex only in HIV infected cells. 18BIO 
derivatives are very promising since they inhibit HIV-1 Tat-dependent transcription at the 
nanomolar level with less toxicity than the original molecule 18BIO. These molecules also 
confer neuronal and microglial protection by reducing both Tat production and release and 
prevent or reduce HIV-associated neurocognitive disease (HAND). 
(iv) Targeting Tat-TAR interaction 
A much more promising approach is to inhibit binding of Tat on the RNA TAR which is 
unique for lentiviruses such as HIV-1. However, although many candidates were tested, all 
failed in clinical trials [110–116]. A series of linear polypeptide analogues have been shown 
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to impede the Tat-TAR interaction [117,118]. Unfortunately, these molecules also bound 
cellular host RNAs. Constrained cyclic peptidomimetics derived from HIV-1 Tat have been 
used to reduce the non-specific binding to RNAs, which is mainly due to a conformational 
flexibility. Using this method, a series of competitive inhibitors of the Tat-TAR interaction 
have been identified and tested in vitro and ex vivo [119–122]. It appears that these 
molecules play a dual role as they inhibit both HIV gene transcription and HIV reverse 
transcription [123]. The dual inhibitory mechanism of these compounds could increase their 
efficiency and selectivity compared to other molecules and therefore deserves further 
attention. Finally, dCA, a chemical derivative of corticostatin, a natural steroidal alkaloid 
isolated from a marine sponge is also very promising [124]. This drug prevents Tat-TAR 
interaction at a very low concentration with a very high therapeutic index (over 8000). These 
results raise the possibility of the design of new drugs belonging to the dCA family that are 
capable to inhibit transcription of the virus in latent reservoirs. Importantly, a reduction of 
deleterious effects of chronical inflammation associated with residual viremia in patients on 
cART are expected [125]. Moreover, one study shows that dCA pretreated infected cells 
were never reactivated when treated with latency-reversing agents (LRAs) [126]. This recent 
work needs further investigation since dCA might induce the formation of new epigenetic 
modifications that mediate a very strong state of latency called “deep latency”[127]. 
All these promising molecules need far more investigation before inclusion in current 
drug regimens. Preclinical and clinical trials are needed to assess the mode of action and to 
define the adverse clinical effects that might preclude their use in treatments aiming to 
manage HIV infection. 
 
4. DING proteins: Potential therapeutic agents against HIV-1 
Proteins from the DING family have potential anti-HIV-1 activities. These proteins are 
involved in HIV gene transcription inhibition [128–132]. DING proteins are widely distributed 
in prokaryotes and eukaryotes [133,134]. Their name comes from the well conserved N-
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 C
ali
fo
rn
ia 
Sa
nta
 B
arb
ara
] a
t 1
2:2
6 0
9 J
un
e 2
01
6 
 
 
16 
 
terminus region beginning DINGG [135]. Surprisingly, genes encoding DING proteins are 
lacking from eukaryotic data bases [136]. In human, DING proteins have been associated 
with several pathologies including rheumatoid arthritis, lithiasis, atherosclerosis and cancer 
[136]. The DING protein p27sj , isolated from the plant Hypericum perforatum, inhibits the 
HIV-1 gene transcription [128]. This protein inhibits LTR-driven transcription in several 
human cell lines, including microglial cells, by inhibiting the interactions of two well-known 
activators of HIV gene transcription, the cellular factor NF-IL6 and the viral transactivator Tat. 
Darbinian et al. reported that p27sj exhibits phosphatase activity dephosphorylating the CTD 
domain of RNA polymerase II [137,138]. Another DING protein, named X-DING CD4, 
isolated from human sera also has anti-HIV activity. This protein has been characterized as a 
human resistant factor (HRF) secreted by HIV-1 resistant cells [139,140]. Furthermore, the 
purified X-DING CD4 protein was able to block LTR-driven expression of a reporter gene as 
well as HIV-1 replication [129]. The Human Phosphate Binding Protein (HPBP), a further 
member of the human DING protein family, has also been identified as a potent anti-HIV-1 
factor [130]. HPBP strongly inhibits HIV-1 replication and the IC50 value is in the range of 5 
nM while the index of selectivity is in the range of 30 to 40. In this range of concentration, 
HPBP is also a potent anti-HIV-1 molecule in Peripheral Blood Lymphocytes and in primary 
macrophages, unlike other anti-HIV-1 drugs. Interestingly, HPBP not only targets 
transcription, it is equally effective against drug resistant HIV strains and wild-type strains. It 
will be important to investigate these molecules and their peptide derivatives in animal 
models for drug resistance. Recently, a DING protein from Pseudomonas aerobacter PA14 
was identified and its structure solved [141]. This protein also suppresses HIV-1 transcription 
and replication in microglial cells. The inhibition of the interaction between NF-KB and the 
HIV-1 promoter DING proteins is a common mechanism of action of all these DING proteins 
[142,143] that could also be used to treat chronic inflammation leading to non-AIDS events 
[144,145]. As suggested for X-DING-CD4 [129], their functions could also uncover a role in 
the innate response to infections including HIV-1 [146]. 
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However, results obtained with DING proteins are still preliminary and await preclinical 
and clinical trials to assess their specificity of action and the adverse clinical effects. A 
pharmacophore model could be useful in the design of peptide derivatives of DING proteins. 
We discuss these aspects in more details in the following sections.  
  
5. How can one improve cART? 
To date, vaccination is unavailable and cART is the only efficient treatment for HIV 
infection until eradication of latent reservoirs is not possible. Introduction of cART in 1996 
has profoundly changed prospects of HIV infection; it transformed the lethal disease into a 
chronic pathology that enables infected patients a nearly normal life span. The development 
of drug resistance remains however one of the main problems encountered with cART. It is 
estimated that resistance to at least one drug of the cART cocktail develops in 10-17% of 
new infections [147]. Further improvement of cART remains crucial, even if some 
improvements are available to prevent virus resistance (mainly a better treatment adherence 
as a result of once a day regimen). One way would be to target HIV transcription. Although 
some new drugs were studied for their efficiency to inhibit HIV transcription and others are 
under investigation, currently no drug is available on the market. One might promote 
discovery and design of transcriptional inhibitors by efforts in the following areas: (i) new 
target identification, (ii) introduction of new technologies, (iii) development of new models to 
test drugs and (iv) improvement of drug delivery. 
 
i. Identifying new targets 
Deciphering the molecular mechanisms underlying transcriptional regulation is 
fundamental since it allows the characterization of potential targets that regulate HIV-1 
transcription. We already pointed out the importance of this approach. Indeed, several 
cellular factors are involved in the establishment and the persistence of HIV-1 latency [61]. 
Targeting these factors reinforces the state of latency. An alternative strategy is to target 
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these factors in order to reactivate HIV-1 transcription and replication. Here the idea is to 
deplete HIV-1 from latent cells and concomitantly eliminate HIV by cART and immunotherapy 
[61,148,149]. Numerous cellular factors have been involved in HIV-1 transcription (for 
example ZACS1 [150] and members of the SEC complex [34,151,152]) and many others 
remain to be discovered. Indeed all these known and not yet discovered factors constitute 
potential targets to silence HIV-1 transcription. A strategy using miRNA combined with cell-
based gene therapy also deserves attention. [153,154]. This strategy permit to specifically 
target cellular factors involved in the control of HIV transcription in infected cells. The knock-
out of the cellular cofactor Tat-SF1, that is known to decrease HIV-1 replication in a T-cell 
line, is an example for its application [155].  
 
ii. Exploiting new technologies 
An increasing number of new technologies such as bioengineering, high-throughput 
screening, computer-aided drug design and combinatorial chemistry completed with NMR, 
SPR or CD measurements (reviewed in [104]) will considerably improve the chances for 
discovery of new drugs. New bioengineering processes based on engineered zinc finger 
transcription factors are now emerging. These proteins are attractive candidates for 
antiretroviral therapy since they repress LTR activity by binding to HIV-1 LTR in a sequence 
specific manner [156,157].  
In silico screening of peptides or small molecules targeting newly identified cellular 
factors involved in HIV-1 transcription may also help to identify new inhibitors of HIV-1 
transcription. Freely available data bases of small molecules and peptides will ease the 
selection and the design of new antiretroviral agents [158]. This approach has allowed the 
identification of new inhibitors targeting the cyclin T1-Tat interaction in the pTEFb complex 
[102] and a HIV-1 transcription inhibitor peptide targeting the cellular phosphatase PP1 [159]. 
Small molecule inhibitors of HIV-1 gene expression identified by elegant cell-based and 
fluorescence-based high-throughput screening assays are promising antiretroviral drugs 
[160,161].  
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A major limitation of peptide derivatives is that they have to be injected. Alternatively 
these potent HIV peptides could be used in emergency e.g. in patients on cART infected with 
multidrug resistant strains. 
The pharmacophore model might also help to design rational treatment and allow 
synthesis of new active drugs. This approach has been used in cancer and HIV-1 therapy. 
Indeed, this new technology allowed the development of HIV-1 integrase inhibitors [162] and 
might be extended to other transcriptional inhibitors. Substituted guanidine indole derivatives, 
also designed by the pharmacophore model, are potential inhibitors of HIV-1 transcription 
[163]. 
In addition, several inhibitors of specific protein-protein interactions have been 
discovered by computer-aided design which could be used in HIV-1 treatments as well [164]. 
A new class of CDK9 inhibitors, 2 phenyl fragments, has been identified and characterized 
by this technique [98]. Optimization of these new compounds is necessary.  
Another interesting approach is to use combination of existing active molecules. Such 
combinations include a quinolone derivative identified as a Tat-mediated transcription 
inhibitor together with the tricyclic core of nevirapine and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). Among all the combinations tested, a transcriptional 
inhibitor in combination with a NNRTIs efficiently inhibited HIV-1 reactivation [165]. Further 
investigations are needed to obtain powerful derivatives. 
Finally, screening natural products is also an option in the design of transcriptional 
inhibitors since several natural compounds repress HIV transcription. Natural products are 
one of the most important sources of new drugs [166,167]. Once an effective natural 
compound is identified, potent derivatives might be synthesized by combinatorial chemical 
approaches. 
Exploring all these new resources helps to select and design new anti-HIV agents. 
Translational approaches using computational tools and pharmacophore models are very 
promising and are used more and more to design rational treatments.  
iii. Development of new models 
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Drug resistance to HIV-1 subtypes is a major problem in HIV-1 treatment. [168,169]. A 
T-cell line has been selected to test drugs on various HIV subtypes [170]. The T- cell line has 
also been used to test the safety and the efficacy of RNAi based gene therapies but should 
be extended to alternative strategies.  
Rhesus macaque monkeys and mice are largely used in animal models for preclinical 
trials [171]. However, studies with monkeys are time-consuming and very costly. On the 
other hand, HIV-1 is not infectious in mice because the virus envelope glycoprotein does not 
bind to the CD4 receptor and the CCR5 coreceptor [172,173]. Moreover, in mice Tat induced 
LTR transcription is 10 to 25 fold less active than in humans, since the transactivator Tat is 
unable to recruit the elongation factor P-TEFb on the TAR-RNA [174,175]. The development 
of humanized mouse models, such as severe combined immunodeficient (SCID) mice, 
provides a powerful way to circumvent these problems. Several improvements have been 
made in the last twenty years in the development of such humanized models [176,177]. In 
BLT mice, the best model used to date, the thymus, liver and hematopoietic stem cells are 
humanized by a triple xenograft procedure [178]. This is currently one of the best model for 
HIV infection and allows to study HIV pathogenesis and to test drugs in preclinical trials 
(reviewed in [179]). Interestingly these mouse models may also be used for the “shock and 
kill strategy” [180]. However these models have to be generated de novo for each 
experiment. Moreover, their handling in specific facilities is difficult and therefore costly. In 
addition, only some parts of the human system can be reconstituted in these mice and this 
limits their use. For example, human myeloid cells cannot be fully reconstituted in mice. 
While lymphoid CD4+ cells are the main reservoir of HIV, cells from the myeloid lineage, e.g. 
the microglial cells are also important reservoirs. Although existing mouse models cannot be 
used to evaluate treatments targeting these cells [177,181], several improvements of the 
humanized mouse models have been developed recently [182]. Producing transgenic mice 
expressing CD4, CCR5 and cyclin T1, which render mouse cells (both lymphoid and myeloid 
cells) susceptible to HIV infections, should help to overcome these limitations and greatly 
facilitate preclinical studies [183].  
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iv. Improving drug delivery 
Tolerance and patient adherence have significantly increased with the introduction of 
the single-tablet regimens. More efficient drug delivery and thus increasing patient 
adherence is another method to increase treatment efficiency and tolerance. Several 
advances have been made in this field, e.g. intracellular delivery of peptides that inhibit the 
Tat-TAR interaction [184].  
The use of 1-1000 nm nanoparticles constitutes a promising tool to reduce toxicity and 
facilitate treatment adherence [185,186]. HIV therapy may improve by specifically targeting 
infected cells and tissues with the possibility to reach sanctuaries e.g. in the brain. The 
nanotechnology-based delivery system could also permit to modulate drug release and to 
prevent drug degradation. These emerging approaches improve bioavailability and therefore 
reduce toxicity [187–189]. Nanotechnology allowed several advances in the combat against 
HIV-1[188,190]. The treatment of HIV in the brain is still a major challenge since most 
antiretroviral drugs cannot cross the blood brain barrier [187,190,191]. Several nano-vehicles 
of drugs such as liposomes, dendrimers, synthetic polymeric nanoparticles, micelles, 
inorganic nanoparticles and natural polymers are available [187,190–195]. A summary of 
antiretroviral drugs used in HIV-1 nanotherapeutics is presented in a recent review [196]. Still 
in the early stage, nanotechnologies await preclinical trials in animal models and clinical trials 
in humans before utilization in HIV treatment. 
 The adherence to treatment also depends significantly on good oral bioavailability of 
the drug. In silico models to test the human oral bioavailability of drugs are under 
development. These computational chemical approaches work as filters to optimize high-
throughput screening of libraries. This method is able to predict the pharmacokinetics 
(Absorption, Distribution, Metabolism, Excretion) and toxicities of a drug [197]. Although still 
in its initial phase, it will certainly improve cART by increasing patient adherence to therapy 
and drastically reducing the drug development cost. 
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6. Expert opinion 
There are several reasons to be optimistic about achieving a cure for HIV infection, 
even if not in a short term [20]. The introduction of cART in 1996 drastically improved the 
management of HIV-1 infection. Unfortunately, the treatment requires lifelong adherence; 
quiescent reservoirs constitute the obstacle for a full HIV eradication. Side effects to cART 
and multidrug resistance against all drugs used in cART emerge because of lifelong 
adherence. Moreover, the development of a residual viremia, whatever its origin, is 
associated with a chronic inflammation that leads to non AIDS-associated pathologies and a 
shorter life expectancy for infected patients compared to healthy individuals. Taken together, 
the remedy of all these issues relies on the development of new drugs improving cART. 
Challenges and requirements for a modified cART to better manage HIV infection are 
discussed in this review and elsewhere [17,198,199].  
We believe that new classes of drugs should target new molecular mechanisms 
involved in the regulation of viral gene expression. This may lead to the absence of virus 
production or to the production of non-infectious particles. We focused in the review on 
transcriptional inhibitors since these can prevent the synthesis of viral proteins such as rev 
and Tat. The design of new treatments is essential for at least three purposes:  
(i) Will improve cART and hence by intensifying cART which is initiated early during 
acute HIV infection may contribute to reduce the size of latent/quiescent 
reservoirs. 
(ii) By preventing synthesis of neurotoxic viral proteins it will reduce the outcome of 
milder form of HAND (reviewed in [200]) 
(iii) Reactivation of the virus with LRA will lead to the synthesis of neurotoxic viral 
proteins and is often associated with CNS inflammation through 
macrophage/microglial activation. Targeting transcription may prevent the 
outcome of brain injuries associated with this “shock and kill strategy” (comments 
in [201]). 
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There are currently several candidates with potent anti-HIV activities that inhibit gene 
transcription in vitro and ex vivo, which deserve attention. However, further investigations are 
needed to test them in vivo. To date, all molecules, except one, targeting HIV transcription 
have failed or did not reach clinical trial. No doubt, the new approaches discussed in this 
review will optimize the potential candidates capable to inhibit specifically HIV transcription. 
The main challenge for the next 10 years will be to assess these new transcriptional 
inhibitors and to find methods to deliver them in preclinical and clinical trials. For example, 
the application of nanotechnologies in trials is presently in an early stage, their wider use will 
improve both bioavailability and bio-distribution of drugs.  
Finally, we point out that several potential drugs targeting HIV transcription have been 
isolated or derived from natural compounds like P27SJ from the plant Hypericum perforatum, 
PA14 from the bacteria Pseudomonas aerobacter and corticostatine from the marine sponge 
Corticium simplex. Natural compounds are still a major source of new drugs; they benefit 
from technical advances in the field of high-throughput screening [202]. As a corollary, this is 
one more good reason to preserve biodiversity.  
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Figure 1: HIV-1 replication cycle. 
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Figure 2: Early and late transcription phase of HIV-1 
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